Freya Biosciences Raises $38 Million to Advance Their Leading Reproductive Drug Prospect

In a follow-on investment, Freya Biosciences has raised $38 million to advance the progression of immunotherapies (a type of medical treatment that harnesses the body’s own immune system to fight diseases). The therapy is targeted at female reproductive health.

The investment phase was headed by Sofinnova Partners and OMX Ventures, with contributions from CE-Ventures and Angelini Ventures.

The money raised will be used by the bioscience firm to further the research progress of its primary treatment prospect, a microbial immunotherapeutic.

The immunotherapy will be studied to determine if it can help women who have an imbalance in their vaginal microbiota and are experiencing fertility issues.

Colleen Acosta, head executive of Freya Biosciences, stated, “Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to their burden on human health. Freya’s initial focus is on the millions of couples around the world who are struggling with infertility.”

Acosta went on to add, “This funding enables us to advance our groundbreaking immunotherapy platform targeting the vaginal microbiota and unlock its therapeutic potential in this area and beyond.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.